What are the fundraising trends in the longevity market?
In our longevity market deck, you will find everything you need to understand the market
SUMMARY
This report analyzes the longevity market across full-year 2024, full-year 2025, and year-to-date 2026 through July 2026. The analysis includes only disclosed equity rounds of $300,000 or more raised by pure-play companies focused on healthspan, aging biology, preventive health, longevity diagnostics, longevity clinics, consumer longevity products, or aging-research platforms.
The longevity market expanded sharply in the last full-year comparison, with total capital rising from about $837 million in 2024 to about $1.92 billion in 2025. But the newest signal is softer: funding so far in 2026 is about $689 million, down from about $1.38 billion over the comparable period in 2025.
The market is not collapsing; it is normalizing after an unusually distorted 2025. Retro Biosciences' $1 billion financing represented about 52% of all 2025 capital, so the 2025 baseline was inflated by one exceptional platform round.
Deal count did not expand with headline capital. The longevity market produced 23 deals in 2024, 21 deals in 2025, and 7 deals so far in 2026, which means the funding story is mainly about larger rounds going to fewer perceived winners rather than a broad increase in funded companies.
Round sizes are highly unequal. The average round rose from about $36 million in 2024 to about $92 million in 2025, while the median round moved only from about $17 million to $20 million. That gap shows that the typical company did not experience the headline boom.
Longevity Therapeutics Developers are the capital spine of the longevity market. Therapeutics captured about 57% of capital in 2024, about 71% in 2025, and roughly 91% so far in 2026.
Preventive Health Platforms are fundable when they look like infrastructure, not generic wellness. Function Health's $298 million 2025 round explains almost all of the category's 2025 capital, showing that investors prefer recurring testing, longitudinal data, and AI-guided health intelligence over broad prevention narratives.
Diagnostics, clinics, and consumer longevity remain investable but secondary. Diagnostics raised about $25 million in 2025, Healthy Aging Clinics raised about $34 million, and Consumer Longevity Brands raised about $82 million, all far below the therapeutic and major platform categories.
North America remains the dominant geography. It captured about 90% of full-year 2025 capital and about 99% of year-to-date 2026 capital, while Europe and Asia-Pacific remain visible but much less consistent as large-round markets.
The practical interpretation is that the longevity market is maturing at the center and still experimenting at the edges. Investors are no longer funding longevity as a vague theme; they are funding companies that can translate healthspan into clinical endpoints, regulatory paths, mechanistic biology, longitudinal data systems, or clinically credible consumer platforms.
This chart, featured in our longevity market deck, illustrates how revenue is distributed across customer segments in the longevity market
Is more or less capital going into the longevity market?
More capital went into the longevity market in the last complete annual comparison, but less capital is going into the longevity market in the freshest year-to-date comparison. Full-year funding rose from about $837 million in 2024 to about $1.92 billion in 2025, while year-to-date 2026 funding is about $689 million, down from about $1.38 billion over the comparable early-July period in 2025.
The 2025 increase should not be read as broad-based market expansion. Retro Biosciences' $1 billion financing alone represented about 52% of full-year 2025 capital, so the headline market more than doubled largely because one company raised an extraordinary platform round.
The outlier-adjusted picture is more restrained. Capital excluding rounds above $50 million fell from about $328 million in 2024 to about $196 million in 2025, which means the ordinary sub-$50 million financing environment actually became smaller even as headline capital rose.
The newest 2026 signal confirms that investors are still active but more selective. So far in 2026, the longevity market has raised about $689 million across 7 deals, which is meaningfully below the comparable 2025 period but still a large amount for a narrow pure-play healthspan category.
The better interpretation is that the longevity market is not abandoned; it is being re-priced after an abnormal 2025. Large capital is still available, but mainly for companies with clinical, regulatory, mechanistic, or platform-scale credibility.
For the underlying market view, see the full longevity market report.
Is longevity funding activity driven by more deals or larger rounds?
Longevity funding activity is driven by larger rounds, not by more deals. Full-year deal count fell from 23 deals in 2024 to 21 deals in 2025, while total capital rose from about $837 million to about $1.92 billion.
The average round size rose from about $36 million in 2024 to about $92 million in 2025. The median round size rose only modestly, from about $17 million to $20 million, which means the typical longevity company did not suddenly raise dramatically more capital.
The concentration metrics tell the same story. The top 3 deals captured about 47% of capital in 2024, but about 74% in 2025. The top 10 captured about 87% in 2024 and about 95% in 2025, while the bottom half of deals fell from about 7.9% of capital to about 4.5%.
The 2026 year-to-date picture still depends on round size rather than deal volume. There are only 7 qualifying deals so far in 2026, and NewLimit's $435 million Series C alone represents about 63% of year-to-date funding.
The practical takeaway is simple: the longevity market is not becoming more active because many more companies are raising. It is becoming more capital-intensive for a small number of perceived winners.
Is longevity capital moving toward later-stage or earlier-stage companies?
Longevity capital is moving toward more proven companies economically, even when stage labels sometimes make the market look earlier-stage. Full-year 2025 looks early-stage on paper because Series A capital represented about $1.04 billion, but that figure is dominated by Retro Biosciences' $1 billion Series A.
Retro's round behaves economically like a mega-platform financing, not a normal early-stage benchmark. That is why stage labels should be treated carefully in the longevity market.
The stronger signal is the movement toward follow-on funding. First financings represented about 43% of deals and about 13% of capital in 2024, but only about 14% of deals and about 4% of capital in 2025.
The 2026 year-to-date signal is even more late-stage by capital. Series B and later rounds account for about 95% of capital so far in 2026, while Seed, Series A, and Unknown-stage rounds account for only about 5%.
The strongest conclusion is that longevity capital is moving toward proof, not simply toward a stage bucket. Investors are rewarding credible mechanisms, clinical development paths, regulatory strategies, and companies that can absorb large technical capital.
This chart, featured in our longevity market deck, compares the main business model options for longevity clinics
Is the longevity market maturing or still experimental?
The longevity market is maturing at the capital center, but it remains experimental at the edges. The maturing signal is that most capital now flows to follow-on rounds, therapeutics platforms, regulated development paths, and companies with clearer proof frameworks.
The strongest maturity indicator is the shift away from first-financing dominance. First financings were about 43% of deals in 2024, fell to about 14% in 2025, and rebounded to about 43% so far in 2026, but those 2026 first financings still represent only about 5% of capital.
The second maturity indicator is therapeutic concentration. Longevity Therapeutics Developers captured about 57% of capital in 2024, about 71% in 2025, and about 91% so far in 2026.
The experimental side remains visible in diagnostics, clinics, consumer longevity, and aging research platforms. Those categories receive financing, but they do not yet produce frequent large rounds across many companies.
The right reading is that the longevity market has a mature core and an experimental periphery. The core is therapeutics and major preventive platforms; the periphery is still testing which clinic, diagnostic, consumer, and research-platform models can scale.
For more detail on how maturity differs by category, see the deeper analysis of the longevity market.
Are new startups still entering the longevity market?
New startups are still entering the longevity market, but new startup formation is no longer the main driver of capital. In 2024, first financings accounted for 10 of 23 deals, or about 43%, while in 2025 they fell to 3 of 21 deals, or about 14%.
The 2025 comparison is important because the market raised much more total capital while becoming less dependent on new entrants. First-financing share of capital fell from about 13% in 2024 to about 4% in 2025.
So far in 2026, new-company formation is visible again by count. First financings account for 3 of 7 deals, or about 43%, but those first financings represent only about $37 million out of $689 million.
That means the longevity market is still open to new entrants, but the bar for large funding has moved higher. New companies can raise seed or Series A capital when they have credible science or positioning, but market-defining dollars go to companies with stronger validation.
Are more investors entering the longevity market?
More high-quality investors are appearing in the longevity market, but the total investor base does not show a simple broadening story. In 2024, the market had about 109 unique disclosed investors and 21 unique tier-1 investors; in 2025, total disclosed investors fell to roughly 70 to 80, while tier-1 investors rose to about 26.
That suggests the investor mix became more prestigious, but not necessarily broader. Full-year 2025 included names such as Kleiner Perkins, Khosla Ventures, Founders Fund, Redpoint, Andreessen Horowitz, Battery Ventures, Eli Lilly, Prelude Growth Partners, Accel, Samsung Next, Value Partners, and M42.
The 2026 year-to-date comparison is too small to overinterpret. So far in 2026, there are about 23 unique disclosed investors, roughly comparable to the 20 to 25 disclosed investors over the comparable period in 2025.
The better interpretation is that the longevity market is attracting stronger investors rather than many more investors. Investor entry is selective, concentrated, and attached to specific proof types rather than broad enthusiasm for the whole category.
This chart, featured in our longevity market deck, illustrates yearly funding for longevity startups
Are top investors getting more or less active in longevity?
Top investors are becoming more visible in longevity, but not necessarily more repeatedly active across many companies. In 2024, seven disclosed investors appeared in more than one deal, including Lifespan Vision Ventures, Andreessen Horowitz or a16z Bio + Health, Hevolution, Khosla Ventures, R42 Group, SeedFolio, and Sofinnova Investments.
In 2025, repeat investors existed, but much of the repetition came from repeat participation in the same company's financing path. Kleiner Perkins, Human Capital, Dimension, and Boost VC appeared in NewLimit-related financings, while Goldcrest Capital and Godfrey Capital appeared in Junevity's seed and extension.
That distinction matters because repeated investment across multiple independent companies is a stronger market-wide conviction signal than following on in one portfolio company. The longevity market has top-tier endorsement, but not yet top-tier saturation.
The 2026 year-to-date signal is thinner still. No disclosed investor appears in more than one included qualifying deal so far in 2026, even though individual rounds include high-quality names such as Founders Fund, Thrive Capital, Greenoaks, Kleiner Perkins, Eli Lilly Ventures, Mubadala, Baillie Gifford, SOSV, and Woodline Partners.
The strongest interpretation is that top investors are willing to write large checks into specific longevity winners, but they are not yet deploying repeatedly across a deep bench of obvious companies.
Which longevity subcategories are gaining momentum?
The subcategories gaining momentum are Longevity Therapeutics Developers first, major Preventive Health Platforms second, and selectively Healthy Aging Clinics and Diagnostics Biomarker Companies in the full-year comparison. The strongest and most durable momentum is in therapeutics.
Therapeutics funding rose from about $477 million in 2024 to about $1.37 billion in 2025, and therapeutics captured about $625 million so far in 2026. The category's capital share moved from about 57% in 2024 to about 71% in 2025 and about 91% in 2026 year-to-date.
Preventive Health Platforms gained full-year momentum from 2024 to 2025, rising from about $219 million to about $304 million. But that momentum is concentrated because Function Health's $298 million Series B drove nearly all 2025 category capital.
Healthy Aging Clinics and Diagnostics Biomarker Companies also improved in the full-year comparison, though from small bases. Clinics rose from about $10 million in 2024 to about $34 million in 2025, while diagnostics rose from about $8 million to about $25 million.
So far in 2026, Consumer Longevity Brands show a fresh signal because L-Nutra and Rapalogix Health together raised about $56.5 million. That signal is preliminary, but it suggests consumer longevity can raise when products have clinical validation, mechanistic claims, or strategic corporate relevance.
For category-level benchmarks, see the longevity market deck.
Which longevity subcategories are losing momentum?
The subcategories losing momentum depend on the comparison window. In the full-year 2025 versus 2024 comparison, Consumer Longevity Brands lost capital share, while in the 2026 year-to-date comparison Preventive Health Platforms, Diagnostics Biomarker Companies, and Aging Research Platforms look weaker because there are no qualifying deals in those categories.
Consumer Longevity Brands declined from about $93 million in 2024 to about $82 million in 2025. That is not a collapse, but the category's capital share fell from about 11% to about 4% because therapeutics and major preventive platforms grew faster.
Aging Research Platforms had a mixed signal. Funding rose from about $30 million in 2024 to $110 million in 2025, but deal count fell from 3 to 1, so the category depended almost entirely on Insilico Medicine's large Series E.
Diagnostics looked better in the full-year comparison but absent in 2026 so far. That absence is notable because diagnostics are central to the longevity narrative, yet investors appear to prefer measurement when it is embedded inside larger platforms rather than sold as a standalone biomarker business.
The practical conclusion is that subcategories lose momentum when they cannot show therapeutic defensibility, recurring data scale, clinical evidence, or a credible intervention loop. Generic wellness language is not enough.
This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity
Which regions are gaining momentum in longevity funding?
North America remains the strongest region, while Asia-Pacific showed the clearest full-year improvement from 2024 to 2025. Europe was stable in absolute dollars but lost relative share because the global market expanded around larger North American and Asia-Pacific rounds.
Full-year North American funding rose from about $751 million in 2024 to about $1.72 billion in 2025. Deal count was almost stable, moving from 17 deals to 16 deals, which means North America's momentum came from larger rounds rather than more companies.
Asia-Pacific gained momentum in the full-year comparison. Funding increased from only about $1.4 million in 2024 to about $115 million in 2025, while deal count rose from 1 to 3.
The Asia-Pacific signal is real but fragile because Insilico Medicine's $110 million round drove most of the region's 2025 capital. Smaller rounds such as Biopeak and Decode Age show regional activity, but not yet a deep large-round market.
So far in 2026, North America has captured about 99% of capital and about 86% of deals. That suggests North America is currently the only region producing large disclosed pure-play longevity rounds at scale.
Which regions are losing momentum in longevity funding?
Europe and Asia-Pacific are losing momentum in the freshest 2026 year-to-date comparison, while Europe also lost relative momentum in the full-year 2025 comparison. North America is not losing momentum; it remains the capital center of the longevity market.
Europe's loss of momentum is clearest in relative terms. European capital was roughly flat from 2024 to 2025, at about $84 million to $85 million, but Europe's share of total capital fell from about 10% to about 4%.
Europe's deal count also fell from 5 deals in 2024 to 2 deals in 2025. That means Europe remained present, but the center of gravity moved further toward North America.
Asia-Pacific gained in full-year 2025 but weakened in 2026 so far. It reached about $115 million across 3 deals in 2025, but has only one qualifying deal so far in 2026, TMRW's $7 million seed round.
Latin America, the Middle East, and Africa remain absent under the strict pure-play definition across the available 2024, 2025, and 2026 year-to-date figures. That means there is no visible disclosed venture-backed pure-play market in those regions under the inclusion standard.
Is the longevity market becoming more global or more regionally concentrated?
The longevity market became somewhat more global in 2025 by deal visibility, but it is becoming more regionally concentrated again in 2026 by capital. Full-year 2025 included activity in North America, Europe, and Asia-Pacific, but large rounds still overwhelmingly happened in North America.
Asia-Pacific's rise from about $1.4 million in 2024 to about $115 million in 2025 gave the market more geographic breadth. Europe also remained active with about $85 million in 2025 capital.
Even so, North America captured about 90% of full-year 2025 capital, almost the same capital share it held in 2024. Asia-Pacific captured about 6%, and Europe captured about 4%.
The 2026 year-to-date signal points back toward concentration. North America has captured about 99% of year-to-date capital, while Europe has no qualifying deal in the included set and Asia-Pacific has one $7 million clinic deal.
The best interpretation is that longevity is globally interesting but regionally concentrated. Demand, science, and company formation exist outside North America, but large disclosed equity rounds remain overwhelmingly North American.
For ongoing regional tracking, see the market report covering longevity geography.
This chart, featured in our longevity market deck, shows how wearable longevity devices have driven growth in the longevity market over time
Is longevity capital moving toward proven winners or new opportunities?
Longevity capital is moving toward proven winners, even though new opportunities still appear by deal count. In 2025, first financings were only about 14% of deals and about 4% of capital, which means almost all dollars went to follow-on companies.
So far in 2026, first financings account for about 43% of deals but only about 5% of capital. That shows the same pattern in a different form: investors are willing to seed new ideas, but large capital goes to companies with prior validation.
Full-year 2025 was especially winner-oriented. Large rounds went to companies such as Retro Biosciences, Function Health, NewLimit, Insilico Medicine, Juvenescence, Aeovian, Blueprint, and Loyal.
The 2026 year-to-date picture reinforces the same conclusion. NewLimit, Loyal, Life Biosciences, and L-Nutra are follow-on companies and together account for most of the year's capital so far.
The longevity market is therefore moving toward proven winners by dollars and new opportunities by count. For market direction, dollars matter more because they determine which companies can run clinical trials, expand platforms, build labs, or scale operations.
Is the longevity market becoming winner-takes-most?
Yes, the longevity market is becoming more winner-takes-most. Full-year 2025 was dramatically more concentrated than 2024, and 2026 so far remains highly concentrated.
The strongest evidence is that the largest 2025 deal captured about 52% of total capital, compared with about 20% for the largest 2024 deal. The top 3 deals captured about 74% of 2025 capital, compared with about 47% in 2024.
The concentration is visible across several metrics. In 2024, the top 5 deals captured about 61% of capital; in 2025, the top 5 captured about 84%.
The 2026 year-to-date market is also winner-takes-most. NewLimit's $435 million Series C represents about 63% of year-to-date capital, while the top 3 deals represent about 89% and the bottom half of deals represent only about 5%.
The practical implication is that headline market growth can be misleading. The longevity market can look booming when one or two companies raise large rounds, even if deal count is flat or down and the median company is raising modestly.
For a fuller concentration view, see the full market view on longevity funding concentration.
Is the next wave of longevity winners becoming visible?
The next wave of longevity winners is becoming visible, but the visibility is concentrated in a small number of proof-rich models rather than spread across the whole market. The clearest emerging winners are therapeutic aging platforms and platform-scale preventive health companies.
NewLimit is the clearest current example. It raised $130 million in 2025, another $45 million later in 2025, and $435 million in 2026, which indicates repeated institutional conviction rather than a one-off event.
Loyal is another visible winner, even though its first market is canine longevity. Loyal raised $45 million in 2024, $22 million in 2025, and $100 million in 2026, suggesting that investors value its FDA-regulated path and concrete longevity-drug framing.
Function Health is the clearest preventive-health platform winner. It raised $53 million in 2024 and $298 million in 2025, separating itself from smaller biomarker or testing companies.
The next wave is less clear in clinics, diagnostics, and consumer longevity. Companies such as Biopeak, Fountain Life, TMRW, GlycanAge, Generation Lab, OneSkin, Blueprint, L-Nutra, and Rapalogix Health show promise, but the funding pattern is smaller and less consistently repeated.
As this slide shows, and as featured in our longevity market deck, online search interest in longevity has been steadily increasing
Is the longevity funding landscape fragmenting or consolidating?
The longevity funding landscape is consolidating by capital but fragmenting by investor participation and business model. Capital is consolidating into a small number of large rounds, while the investor base spans biotech investors, generalist venture funds, strategic corporates, sovereign investors, consumer-growth investors, and specialist longevity investors.
The consolidation side is clear. In 2025, the top 3 rounds captured about 74% of total capital, and the top 10 captured about 95%.
So far in 2026, the top 3 rounds captured about 89% of capital. That is capital consolidation around a few companies.
The fragmentation side is also clear. In 2024, seven investors appeared in more than one disclosed deal; in 2025, repeat investors existed but were often tied to the same company or a narrow cluster; so far in 2026, no disclosed investor appears in more than one included qualifying deal.
The best interpretation is that the longevity market is consolidating around winners while the search for the winning business model remains fragmented outside therapeutics. Investors are still experimenting with how longevity becomes a business, but they are increasingly decisive when a company looks like a true platform winner.
Where is investor attention shifting in longevity?
Investor attention in the longevity market is shifting toward regulated or regulation-adjacent proof. The clearest areas of attention are therapeutic aging platforms, epigenetic reprogramming, cellular rejuvenation, mTOR and senescence biology, FDA-recognizable pathways, and preventive-health systems that generate longitudinal biomarker data.
The most obvious shift is toward therapeutics. Longevity Therapeutics Developers captured about $477 million in 2024, about $1.37 billion in 2025, and about $625 million so far in 2026.
Investor attention is also shifting toward companies that translate longevity into accepted underwriting stories. BioAge linked aging biology to metabolic disease; NewLimit links reprogramming to clinical development; Loyal links longevity to an FDA-regulated canine drug pathway; Function Health links preventive health to recurring lab data and AI-guided health intelligence.
Preventive-health attention is becoming more selective. Function Health raised $298 million in 2025, but there are no qualifying Preventive Health Platform deals so far in 2026, which suggests investors are excited about infrastructure-like prevention rather than generic preventive care.
Consumer longevity attention is shifting toward brands with scientific defensibility. L-Nutra, Timeline, OneSkin, Blueprint, One Bio, and Rapalogix show that consumer longevity is fundable when the company has a proprietary ingredient, biological mechanism, clinical evidence, founder-led demand, or strategic corporate relevance.
For more on where investor attention is moving, see the longevity market report.
INSIGHTS
The insights below come from reviewing disclosed equity funding in the longevity market across full-year 2024, full-year 2025, and year-to-date 2026 through July 2026.
- The longevity market's apparent 2025 boom was real at the headline level but fragile underneath. Full-year capital rose from about $837 million in 2024 to about $1.92 billion in 2025, but capital excluding rounds above $50 million fell from about $328 million to about $196 million.
- The market's center of gravity is no longer longevity as a broad theme. The largest rounds cluster around aging biology translated into therapeutic mechanisms, clinical pathways, longitudinal data systems, or other fundable proof structures.
- The median company did not experience the same funding boom suggested by headline totals. The 2025 average round was about $92 million, but the median was only $20 million, which means the typical financing was far smaller than the headline average implies.
- Retro Biosciences' $1 billion Series A makes stage analysis unusually dangerous. Treating that round as normal Series A capital would falsely suggest that early-stage longevity financing exploded, when the better interpretation is that one mega-platform absorbed half the year's capital.
- The strongest market signal is not deal count but concentration. Deal count declined from 23 in 2024 to 21 in 2025, while the top 3 capital share rose from about 47% to about 74%.
- The longevity market is becoming more mature by dollars and less experimental by funding behavior. First financings fell from about 43% of deals in 2024 to about 14% in 2025, while follow-on rounds captured nearly all 2025 capital.
- The 2026 year-to-date rebound in first-financing share should not be mistaken for a broad seed boom. First financings are about 43% of deals so far in 2026, but only about 5% of capital.
- Therapeutics have become the market's underwriting anchor. Longevity Therapeutics Developers increased their capital share from about 57% in 2024 to about 71% in 2025 and about 91% so far in 2026.
- The market rewards companies that translate aging into disease, pathway, or regulatory language. Aging as a general ambition is less fundable than aging expressed as reprogramming, mTOR biology, senescence, metabolic disease, canine FDA approval, or a defined clinical endpoint.
- Preventive-health platforms are fundable only when they look like infrastructure. Function Health's $298 million 2025 round shows that recurring testing, longitudinal data, and AI-guided health intelligence can attract capital, while generic prevention does not show the same funding depth.
- Diagnostics remain more strategically important than financially powerful. Diagnostics Biomarker Companies raised only about $8 million in 2024 and about $25 million in 2025, which means measurement is respected but not yet treated as the main venture-scale value pool.
- Clinic models are investable but still constrained by scalability questions. Healthy Aging Clinics increased from about $10 million in 2024 to about $34 million in 2025, but their capital share remained below 2% of the 2025 market.
- Consumer longevity is not a volume category; it is an exception category. Large consumer rounds require proprietary science, clinical validation, founder-led demand, or strategic brand logic rather than broad anti-aging positioning.
- North America is not merely leading the longevity market; it is structurally dominant. North America captured about 90% of full-year 2025 capital and about 99% of 2026 year-to-date capital.
- Europe is scientifically present but financially under-scaled. European capital was roughly flat from about $84 million to $85 million from 2024 to 2025, but Europe's global capital share fell from about 10% to about 4%.
- Asia-Pacific's 2025 improvement was meaningful but not yet deep. Asia-Pacific funding rose to about $115 million in 2025, but most of that came from Insilico Medicine, making the regional signal dependent on one large company.
- The market's investor base is prestigious but not yet dense. Tier-1 investors increased in visibility, but repeat investor activity across multiple independent companies remains thin.
- The longevity market is consolidating around companies, not around investors. Capital is concentrated in a few companies, while investor participation remains spread across bespoke syndicates.
- Biological-age measurement is more powerful as part of a feedback loop than as a standalone business. The small standalone diagnostics totals contrast with larger preventive-platform rounds that embed testing into longitudinal health management.
- The strongest screening rule for future longevity deals is proof translation. Companies that convert longevity into a clinical endpoint, regulatory path, defensible biological mechanism, longitudinal data asset, or clinically validated product are far more likely to raise large rounds than companies selling broad health optimization.
This chart, featured in our longevity market deck, shows how longevity plan technology has evolved over time
OUR METHODOLOGY TO BUILD THIS TRACKER
We built this longevity funding tracker by reviewing publicly disclosed equity rounds raised by pure-play longevity companies across full-year 2024, full-year 2025, and year-to-date 2026 through July 2026. A company counts as pure-play when more than 80% of its activity is dedicated to extending healthspan, slowing aging, improving aging-related decline, or optimizing long-term health through science, medicine, or technology.
We applied four core filters. First, we included equity rounds only, so grants, debt, structured financings, acquisitions, IPOs, SPAC transactions, and business combinations were excluded. Second, we only counted disclosed rounds of $300,000 or more. Third, we only kept companies that fit the strict longevity definition, excluding generic healthcare, wellness, beauty, fitness, eldercare, financial products, and disease-first businesses that did not explicitly position around longevity or healthspan. Fourth, every included round had to be confirmed by a direct company announcement, press release, investor or law-firm announcement, tier-1 media report, specialist industry source, or credible regional publication.
Undisclosed-amount rounds are excluded because including them would distort dollar-based metrics such as total capital, average round size, median round size, capital concentration, and category share. Borderline cases are treated conservatively: animal longevity, whole-body screening, consumer products, clinics, and disease-focused therapeutics are included only when the company explicitly ties the product or platform to longevity, healthspan, biological aging, aging biology, or long-term preventive health.
Related blog posts
- The latest developments shaping the longevity market
- The most recent news in the longevity market
- How large is the longevity market in reality?
- The most recent funding news in the longevity market
- The evolution of funding activity in the longevity market
- The startups that have raised the most funding in the longevity market
